Table 3.
Reasons for discontinuation during the study
| Reason for discontinuation, n (%) |
Placebo |
OROS MPH |
|
|---|---|---|---|
| (n = 97) |
54 mg/day |
72 mg/day |
|
| (n = 87) | (n = 92) | ||
| Discontinued |
29 (29.9) |
32 (36.8) |
37 (40.2) |
| Adverse event |
2 (2.1) |
15 (17.2) |
19 (20.7) |
| Lack of efficacy |
14 (14.4) |
1 (1.1) |
4 (4.3) |
| Noncompliance |
3 (3.1) |
5 (5.7) |
5 (5.4) |
| Consent withdrawal |
4 (4.1) |
2 (2.3) |
3 (3.3) |
| Loss to follow-up |
5 (5.2) |
1 (1.1) |
0 |
| Sponsor’s decision |
0 |
2 (2.3) |
0 |
| Ineligibility to continue the study |
0 |
1 (1.1) |
1 (1.1) |
| Other | 1 (1.0) | 5 (5.7) | 5 (5.4) |